{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:28Z","timestamp":1794047488080,"version":"4.8.0"},"reference-count":43,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) poses a major challenge in hemophilia A (HA) treatment. The formation of FVIII inhibitors is a CD4+ T-cell-dependent mechanism which includes antigen presenting cells (APC), B- and T-helper lymphocytes. APC present FVIII-derived peptides on major histocompatibility complex class II (MHC-II) to CD4+ T cells. We previously established a mass spectrometry-based approach to delineate the FVIII repertoire presented on HLA-DR and HLA-DQ. In this study, specific attention was directed towards the identification of FVIII peptides presented on HLA-DP. A data-set of naturally processed FVIII peptides was generated by incubating human FVIII with immature monocyte-derived dendritic cells (moDC) from HLA-typed healthy donors. Using this method, we identified 176 to 1,352 different HLA-DP presented peptides per donor, including 26 different FVIII-derived peptides. The most frequently presented peptides derived from the A3 and C2 domains of FVIII. Comparison of the FVIII repertoire presented on HLA-DP with that presented on HLA-DR revealed considerable overlap but also suggested preferential presentation of specific peptides on either HLA-DR or HLA-DP. Fourteen FVIII peptides presented on HLA-DP were synthesized and evaluated for their binding ability to the commonly expressed HLA-DP4 molecule which is highly prevalent in the Caucasian population. Peptide binding studies showed that 7 of 14 peptides competed with a reference peptide to HLA-DP4. Interestingly, an A3 domain-derived peptide bound with high affinity to HLA-DP4, positioning this peptide as a prime candidate for the development of novel peptide-based tolerogenic strategies for FVIII inhibitors.<\/jats:p>","DOI":"10.3324\/haematol.2024.286204","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T03:42:02Z","timestamp":1733974922000},"page":"1316-1327","source":"Crossref","is-referenced-by-count":3,"title":["FVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4"],"prefix":"10.3324","volume":"110","author":[{"given":"Mariarosaria","family":"Miranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarke Endel","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batoul","family":"Wehbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Porcheddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris P.J.","family":"Van Alphen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kaijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Lacroix-Desmazes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje","family":"Van den Biggelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Maillere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Voorberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"EDUC8 Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"75588","doi-asserted-by":"crossref","unstructured":"Mannucci PM. Hemophilia treatment innovation: 50 years of progress and more to come. J Thromb Haemost. 2023; 21(3):403-412.","DOI":"10.1016\/j.jtha.2022.12.029"},{"key":"75589","doi-asserted-by":"crossref","unstructured":"Pratt KP, Arruda VR, Lacroix-Desmazes S. Inhibitors-recent insights. Haemophilia. 2021; 27(S3):28-36.","DOI":"10.1111\/hae.14077"},{"key":"75590","doi-asserted-by":"crossref","unstructured":"Lacroix-Desmazes S, Voorberg J, Lillicrap D, Scott DW, Pratt KP. Tolerating factor VIII: recent progress. Front Immunol. 2019; 10:2991.","DOI":"10.3389\/fimmu.2019.02991"},{"key":"75591","doi-asserted-by":"crossref","unstructured":"Childers KC, Peters SC, Spiegel PC. Structural insights into blood coagulation factor VIII: procoagulant complexes, membrane binding, and antibody inhibition. J Thromb Haemost. 2022; 20(9):1957-1970.","DOI":"10.1111\/jth.15793"},{"key":"75592","doi-asserted-by":"crossref","unstructured":"Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021; 397(10274):630-640.","DOI":"10.1016\/S0140-6736(20)32722-7"},{"key":"75593","doi-asserted-by":"crossref","unstructured":"Mahlangu J, Iorio A, Kenet G., Emicizumab state-of-the-art update. Haemophilia. 2022; 28(Suppl 4):103-110.","DOI":"10.1111\/hae.14524"},{"key":"75594","doi-asserted-by":"crossref","unstructured":"Meeks SL, Zimowski KL. Haemophilia in the era of novel therapies: where do inhibitors feature in the new landscape?. Haemophilia. 2024; 30(Suppl 3):95-102.","DOI":"10.1111\/hae.14982"},{"key":"75595","doi-asserted-by":"crossref","unstructured":"Pratt KP. Inhibitory antibodies in hemophilia A. Curr Opin Hematol. 2012; 19(5):399-405.","DOI":"10.1097\/MOH.0b013e328356ed37"},{"key":"75596","doi-asserted-by":"crossref","unstructured":"Kaczmarek R, Pineros AR, Patterson PE. Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen presenting cells. Blood. 2023; 142(3):290-305.","DOI":"10.1182\/blood.2022018937"},{"key":"75597","doi-asserted-by":"crossref","unstructured":"Matino D, Tieu P, Chan A. Molecular mechanisms of inhibitor development in hemophilia. Mediterr J Hematol Infect Dis. 2020; 12(1):e2020001.","DOI":"10.4084\/mjhid.2020.001"},{"key":"75598","doi-asserted-by":"crossref","unstructured":"Prezotti ANL, Frade-Guanaes JO, Yamaguti-Hayakawa GG, Ozelo MC. Immunogenicity of current and new therapies for hemophilia A. Pharmaceuticals (Basel). 2022; 15(8):911.","DOI":"10.3390\/ph15080911"},{"key":"75599","doi-asserted-by":"crossref","unstructured":"Ettinger RA, Liberman JA, Gunasekera D. FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity. Blood Adv. 2018; 2(4):309-322.","DOI":"10.1182\/bloodadvances.2017013482"},{"key":"75600","doi-asserted-by":"crossref","unstructured":"Winterling K, Martin WD, De Groot AS, Daufenbach J, Kistner S, Sch\u00fcttrumpf J. Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach. J Thromb Haemost. 2021; 19(9):2161-2170.","DOI":"10.1111\/jth.15413"},{"key":"75601","doi-asserted-by":"crossref","unstructured":"Pletinckx K, Nicolson KS, Streeter HB. Antigen-specific immunotherapy with apitopes suppresses generation of FVIII inhibitor antibodies in HLA-transgenic mice. Blood Adv. 2022; 6(7):2069-2080.","DOI":"10.1182\/bloodadvances.2021004451"},{"key":"75602","doi-asserted-by":"crossref","unstructured":"Maldonado RA, LaMothe RA, Ferrari JD. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci U S A. 2015; 112(2):E156-165.","DOI":"10.1073\/pnas.1408686111"},{"key":"75603","doi-asserted-by":"crossref","unstructured":"Kelly A, Trowsdale J. Genetics of antigen processing and presentation. Immunogenetics. 2019; 71(3):161-170.","DOI":"10.1007\/s00251-018-1082-2"},{"key":"75604","doi-asserted-by":"crossref","unstructured":"Jankowski W, Park Y, McGill J. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products. Blood Adv. 2019; 3(9):1429-1440.","DOI":"10.1182\/bloodadvances.2018030452"},{"key":"75605","doi-asserted-by":"crossref","unstructured":"van Haren SD, Herczenik E, ten Brinke A, Mertens K, Voorberg J, Meijer AB. HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII. Mol Cell Proteomics. 2011; 10(6):M110.002246.","DOI":"10.1074\/mcp.M110.002246"},{"key":"75606","doi-asserted-by":"crossref","unstructured":"van Haren SD, Wroblewska A, Herczenik E. Limited promiscuity of HLA-DRB1 presented peptides derived of blood coagulation factor VIII. PLoS One. 2013; 8(11):e80239.","DOI":"10.1371\/journal.pone.0080239"},{"key":"75607","doi-asserted-by":"crossref","unstructured":"Peyron I, Hartholt RB, Pedr\u00f3-Cos L. Comparative profiling of HLA-DR and HLA-DQ associated factor VIII peptides presented by monocyte-derived dendritic cells. Haematologica. 2018; 103(1):172-178.","DOI":"10.3324\/haematol.2017.175083"},{"key":"75608","doi-asserted-by":"crossref","unstructured":"Porcheddu V, Lhomme G, Giraudet R, Correia E, Maill\u00e8re B. The self-reactive FVIII T cell repertoire in healthy individuals relies on a short set of epitopes and public clonotypes. Front Immunol. 2024; 15:1345195.","DOI":"10.3389\/fimmu.2024.1345195"},{"key":"75609","doi-asserted-by":"crossref","unstructured":"Reding MT, Wu H, Krampf M. CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost. 1999; 82(2):509-515.","DOI":"10.1055\/s-0037-1615873"},{"key":"75610","doi-asserted-by":"crossref","unstructured":"Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. Lineages of human T-cell clones, including T helper 17\/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood. 2009; 114(7):1423-1428.","DOI":"10.1182\/blood-2009-01-200725"},{"key":"75611","doi-asserted-by":"crossref","unstructured":"Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P. Haemophilia. 2010; 16(102):44-55.","DOI":"10.1111\/j.1365-2516.2008.01905.x"},{"key":"75612","doi-asserted-by":"crossref","unstructured":"James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide. J Thromb Haemost. 2007; 5(12):2399-2407.","DOI":"10.1111\/j.1538-7836.2007.02762.x"},{"key":"75613","doi-asserted-by":"crossref","unstructured":"Ettinger RA, Liberman JA, Gunasekera D. FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity. Blood Adv. 2018; 2(4):309-322.","DOI":"10.1182\/bloodadvances.2017013482"},{"key":"75614","doi-asserted-by":"crossref","unstructured":"Ettinger RA, Paz P, James EA. T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire. Blood. 2016; 128(16):2043-2054.","DOI":"10.1182\/blood-2015-11-682468"},{"key":"75615","doi-asserted-by":"crossref","unstructured":"Jacquemin M, Vantomme V, Buhot C. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild\/moderate hemophilia A. Blood. 2003; 101(4):1351-1358.","DOI":"10.1182\/blood-2002-05-1369"},{"key":"75616","doi-asserted-by":"crossref","unstructured":"Meunier S, Menier C, Marcon E, Lacroix-Desmazes S, Maill\u00e8re B. CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise na\u00efve and memory cells. Blood Adv. 2017; 1(21):1842-1847.","DOI":"10.1182\/bloodadvances.2017008706"},{"key":"75617","doi-asserted-by":"crossref","unstructured":"Menier C, Meunier S, Porcheddu V. Frequency of natural regulatory T cells specific for factor VIII in the peripheral blood of healthy donors. Eur J Immunol. 2024; 54(4):e2350506.","DOI":"10.1002\/eji.202350506"},{"key":"75618","doi-asserted-by":"crossref","unstructured":"Diego VP, Luu BW, Hofmann M. Quantitative HLA-class-II\/ factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A. J Thromb Haemost. 2020; 18(1):201-216.","DOI":"10.1111\/jth.14647"},{"key":"75619","doi-asserted-by":"crossref","unstructured":"Castelli FA, Buhot C, Sanson A. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptidebinding specificity. J Immunol. 2002; 169(12):6928-6934.","DOI":"10.4049\/jimmunol.169.12.6928"},{"key":"75620","doi-asserted-by":"crossref","unstructured":"Shaw S, Ziegler A, DeMars R. Specificity of monoclonal antibodies directed against human and murine class II histocompatibility antigens as analyzed by binding to HLA-deletion mutant cell lines. Hum Immunol. 1985; 12(4):191-211.","DOI":"10.1016\/0198-8859(85)90336-2"},{"key":"75621","doi-asserted-by":"crossref","unstructured":"Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol. 2005; 23:975-1028.","DOI":"10.1146\/annurev.immunol.22.012703.104538"},{"key":"75622","doi-asserted-by":"crossref","unstructured":"Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee H-G. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics. 1994; 39(4):230-242.","DOI":"10.1007\/BF00188785"},{"key":"75623","doi-asserted-by":"crossref","unstructured":"Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013; 4(1):59-72.","DOI":"10.1177\/2040620712464509"},{"key":"75624","doi-asserted-by":"crossref","unstructured":"Anderson RP, Jabri B. Vaccine against autoimmune disease: antigen-specific immunotherapy. Curr Opin Immunol. 2013; 25(3):410-417.","DOI":"10.1016\/j.coi.2013.02.004"},{"key":"75625","doi-asserted-by":"crossref","unstructured":"Pearce SHS, Dayan C, Wraith DC. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves\u2019 hyperthyroidism: a phase I study. Thyroid. 2019; 29(7):1003-1011.","DOI":"10.1089\/thy.2019.0036"},{"key":"75626","doi-asserted-by":"crossref","unstructured":"Prakken BJ, Samodal R, Le TD. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2004; 101(12):4228-4233.","DOI":"10.1073\/pnas.0400061101"},{"key":"75627","doi-asserted-by":"crossref","unstructured":"Koffeman EC, Genovese M, Amox D. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum. 2009; 60(11):3207-3216.","DOI":"10.1002\/art.24916"},{"key":"75628","doi-asserted-by":"crossref","unstructured":"Chataway J, Martin K, Barrell K, Sharrack B, Stolt P, Wraith DC. Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis. Neurology. 2018; 90(11):e955-e962.","DOI":"10.1212\/WNL.0000000000005118"},{"key":"75629","doi-asserted-by":"crossref","unstructured":"Goel G, King T, Daveson AJ. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. Lancet Gastroenterol Hepatol. 2017; 2(7):479-493.","DOI":"10.1016\/S2468-1253(17)30110-3"},{"key":"75630","doi-asserted-by":"crossref","unstructured":"Zhang A-H, Rossi RJ, Yoon J, Wang H, Scott DW. Tolerogenic nanoparticles to induce immunologic tolerance: prevention and reversal of FVIII inhibitor formation. Cell Immunol. 2016; 301:74-81.","DOI":"10.1016\/j.cellimm.2015.11.004"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11868\/77882","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11868\/78414","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11868\/77882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:52Z","timestamp":1794046072000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286204","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,12]]}}}